About Us

At BMed Global  we believe in the transformative power of psychedelics to foster mental health and collective well-being. We are inspired by the idea that the next evolutionary step will not be individual but communal: a network of awakened and connected individuals guided by empathy and respect for life. 
 
Our mission is to weave this global community, exploring psychedelic-based therapeutic approaches that drive profound personal and social transformation. Together, we strive toward a more conscious future in harmony with nature and human potential.

We aspire to become a center of excellence to help develop and validate the use of transformative psychedelic-based therapeutic approaches for well-being and mental health

Founders

Karina Bertolotto

CEO | Founder

Bachelor’s Degree in Psychology
Catholic University of Uruguay

Master’s in Humanistic Psychotherapy
Erich Fromm Institute, Barcelona

PhD Candidate at Queen Margaret University

Professor and Academic Coordinator in the area of psychotherapy for the Master’s in Music Therapy at the University of Barcelona

Professional Member of Eurotas
European Transpersonal Psychology Association

Trained in the SAT Program in Integrative Psychology by Claudio Naranjo

Since 2007, she has been organizing the program for 5 years in California, Canada, Brazil, China, and Uruguay.

Disciple of Anna Halprin, Stan Grof, Hank Wesselman, Andrew Harvey

Josep M. Fabregas

MD President BMed and Strategic Advisor

Physician specialized in psychiatry
With over 40 years of experience in the profession and extensive training in various areas of the specialty.

Expert in drug addiction, alcoholism, gambling addiction, and personality disorders
among others, being from the start a national and international reference in the treatment of these conditions.

Founded and directs the Center for Addiction Research and Treatment
CITA, in Catalonia

Founded and directs the Institute of Applied Amazonian Ethnopsychology
IDEAA, in Brazil

Lina Williamson

DVM, PhD. Strategic
Advisor

DVM, PhD.
Scientist and serial entrepreneur in multiple areas of the healthcare sector with global experience in the biopharmaceutical industry, translational medicine, and academic innovation.

Has been involved in the creation of over a dozen start-ups
Working closely with hundreds of researchers globally for the development of new findings in the fields of biomedicine.

Has collaborated with institutions such as Harvard Medical School, Brigham and Women’s Hospital, and companies like Novartis.

What Do We Do?

To meet the growing demand for certified therapists and companions, we focus on:

To Spread

With the current resurgence in psychedelic medicine research and related treatments approved for medical use, we consider it essential to disseminate information about these advancements to both the medical community and the general public.

To Train

We develop programs with a wide range of courses that introduce a variety of core topics, including psychedelic pharmacology, neurobiology, and clinical applications; as well as explorations of indigenous uses of master plants, ethical challenges, treatment models, and more.

To Empower

To future therapists, individuals interested in integrating psychedelic medicine and learning about its therapeutic benefits; including caregivers and advocates aiming to support the health and well-being of their patients.

Why?

We believe that people deserve the opportunity to be healthy and feel fulfilled in order to offer the best of themselves and contribute to the world in which we live.

Taking into account the regulatory framework of each country regarding the use of psychedelic plants and approved synthetics, BMed Global was formed to enable access to psychedelic medicine in mental health.

Synergy with the local Associations and Partnerships.

BMed Global  collaborates with diverse entities and international partnerships to foster a connected and thriving global community. 

Creation of assisted therapeutic protocols

Since its inception, BMed has brought together a multidisciplinary group of collaborators with experience in psychiatry, psychology, education, ethnobotany, and communications. The team’s intent is to use this approach to rapidly advance in the creation of psychedelic-assisted therapeutic protocols for common conditions that affect the well-being of humanity.